[go: up one dir, main page]

FR20C1034I1 - Traitement combiné de tumeurs exprimant la cd38 - Google Patents

Traitement combiné de tumeurs exprimant la cd38

Info

Publication number
FR20C1034I1
FR20C1034I1 FR20C1034C FR20C1034C FR20C1034I1 FR 20C1034 I1 FR20C1034 I1 FR 20C1034I1 FR 20C1034 C FR20C1034 C FR 20C1034C FR 20C1034 C FR20C1034 C FR 20C1034C FR 20C1034 I1 FR20C1034 I1 FR 20C1034I1
Authority
FR
France
Prior art keywords
combination treatment
expressing tumors
tumors
expressing
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1034C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1034(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genmab AS filed Critical Genmab AS
Publication of FR20C1034I1 publication Critical patent/FR20C1034I1/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
FR20C1034C 2006-09-26 2020-07-16 Traitement combiné de tumeurs exprimant la cd38 Active FR20C1034I1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84732906P 2006-09-26 2006-09-26
DKPA200601232 2006-09-26
EP07817816.7A EP2081595B1 (fr) 2006-09-26 2007-09-26 Traitement combiné de tumeurs exprimant la cd38

Publications (1)

Publication Number Publication Date
FR20C1034I1 true FR20C1034I1 (fr) 2020-10-02

Family

ID=39156080

Family Applications (6)

Application Number Title Priority Date Filing Date
FR19C1056C Active FR19C1056I1 (fr) 2006-09-26 2019-10-09 Traitement combiné de tumeurs exprimant la cd38
FR19C1055C Active FR19C1055I1 (fr) 2006-09-26 2019-10-09 Traitement combiné de tumeurs exprimant la cd38
FR19C1057C Active FR19C1057I1 (fr) 2006-09-26 2019-10-09 Traitement combiné de tumeurs exprimant la cd38
FR20C1034C Active FR20C1034I1 (fr) 2006-09-26 2020-07-16 Traitement combiné de tumeurs exprimant la cd38
FR21C1062C Active FR21C1062I1 (fr) 2006-09-26 2021-12-20 Traitement combiné de tumeurs exprimant la cd38
FR21C1063C Active FR21C1063I1 (fr) 2006-09-26 2021-12-20 Traitement combiné de tumeurs exprimant la cd38

Family Applications Before (3)

Application Number Title Priority Date Filing Date
FR19C1056C Active FR19C1056I1 (fr) 2006-09-26 2019-10-09 Traitement combiné de tumeurs exprimant la cd38
FR19C1055C Active FR19C1055I1 (fr) 2006-09-26 2019-10-09 Traitement combiné de tumeurs exprimant la cd38
FR19C1057C Active FR19C1057I1 (fr) 2006-09-26 2019-10-09 Traitement combiné de tumeurs exprimant la cd38

Family Applications After (2)

Application Number Title Priority Date Filing Date
FR21C1062C Active FR21C1062I1 (fr) 2006-09-26 2021-12-20 Traitement combiné de tumeurs exprimant la cd38
FR21C1063C Active FR21C1063I1 (fr) 2006-09-26 2021-12-20 Traitement combiné de tumeurs exprimant la cd38

Country Status (23)

Country Link
US (4) US9040050B2 (fr)
EP (3) EP3569245A1 (fr)
JP (6) JP5476122B2 (fr)
AU (2) AU2007302448C1 (fr)
CA (1) CA2664740C (fr)
CY (7) CY1121813T1 (fr)
DK (1) DK2081595T3 (fr)
EA (1) EA034877B1 (fr)
ES (1) ES2732278T3 (fr)
FR (6) FR19C1056I1 (fr)
HR (1) HRP20191115T1 (fr)
HU (6) HUE044136T2 (fr)
IL (2) IL197727A (fr)
LT (7) LT2081595T (fr)
LU (3) LUC00128I2 (fr)
ME (1) ME03503B (fr)
NZ (1) NZ576122A (fr)
PL (1) PL2081595T3 (fr)
PT (1) PT2081595T (fr)
RS (1) RS59005B1 (fr)
SI (1) SI2081595T1 (fr)
TR (1) TR201910145T4 (fr)
WO (1) WO2008037257A2 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119119271A (zh) * 2005-03-23 2024-12-13 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
PT2081595T (pt) * 2006-09-26 2019-07-16 Genmab As Anti-cd38 mais corticosteroides mais um quimioterápico não corticosteroide para tratar tumores
EP2191841A1 (fr) * 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et vincristine
EP2191840A1 (fr) * 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et melphalan
EP2191842A1 (fr) * 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cytarabine
WO2011050180A1 (fr) * 2009-10-21 2011-04-28 Immunogen, Inc. Nouveau régime d'administration des doses et méthode de traitement
LT2580243T (lt) 2010-06-09 2020-01-27 Genmab A/S Antikūnai prieš žmogaus cd38
US8877899B2 (en) * 2010-09-27 2014-11-04 Morphosys Ag Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
LT2707030T (lt) 2011-05-09 2020-07-10 Mayo Foundation For Medical Education And Research Vėžio gydymas
EA201700111A1 (ru) 2011-10-28 2018-02-28 Тева Фармасьютикал Австралия Пти Лтд Полипептидные конструкции и их применение
HUE036518T2 (hu) 2012-09-25 2018-07-30 Morphosys Ag Kombinációk és alkalmazásaik
AU2013327638B2 (en) 2012-10-01 2018-06-14 Mayo Foundation For Medical Education And Research Cancer treatments
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US20160022813A1 (en) * 2013-03-13 2016-01-28 Sanofi Compositions comprising anti-cd38 antibodies and carfilzomib
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
NZ713641A (en) 2013-04-29 2019-08-30 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US9732154B2 (en) * 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
UA119352C2 (uk) * 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
CA2952424C (fr) 2014-06-16 2019-07-23 Mayo Foundation For Medical Education And Research Traitement de myelomes
EA035098B1 (ru) * 2014-07-31 2020-04-27 Санофи Способ лечения рецидивирующей и/или рефрактерной множественной миеломы
US10617757B2 (en) * 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
SG11201701867SA (en) * 2014-09-09 2017-04-27 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
KR102639037B1 (ko) 2014-10-29 2024-02-20 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 인터페론 α2b 변이체
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
ES2862708T3 (es) * 2015-05-13 2021-10-07 Morphosys Ag Tratamiento del mieloma múltiple (MM)
JP6827426B2 (ja) * 2015-05-20 2021-02-10 ヤンセン バイオテツク，インコーポレーテツド 軽鎖アミロイドーシス及びその他のｃｄ３８陽性血液悪性疾患の治療のための抗ｃｄ３８抗体
JP6816038B2 (ja) 2015-06-22 2021-01-20 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体及びサバイビン阻害剤による血液悪性疾患の併用療法
US20170044265A1 (en) * 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
BR112017027990A2 (pt) * 2015-06-24 2018-08-28 Janssen Biotech, Inc. modulação imune e tratamento de tumores sólidos com anticorpos que se ligam especificamente ao cd38
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
PH12018500950B1 (en) * 2015-11-03 2023-09-20 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
US11571469B2 (en) 2016-01-07 2023-02-07 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
CA3014531A1 (fr) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Traitements des cancers hematologiques
US11878061B2 (en) 2016-03-21 2024-01-23 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
EP3432926A4 (fr) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research Procédés de réduction de la toxicité d'un médicament chimiothérapeutique
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
RU2019109211A (ru) 2016-09-01 2020-10-01 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Композиции, содержащие носитель-pd-l1-связывающий агент для лечения рака
JP2019526579A (ja) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｔ細胞癌を標的とする為の方法及び組成物
WO2018048958A1 (fr) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Compositions d'agents de liaison, de paclitaxel et d'albumine et leurs procédés d'utilisation et de production
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
WO2018098348A1 (fr) * 2016-11-23 2018-05-31 Acetylon Pharmaceuticals, Inc. Combinaisons pharmaceutiques comprenant un inhibiteur d'histone désacétylase et un inhibiteur de cd38 et leurs méthodes d'utilisation
EP4104841A1 (fr) 2016-12-09 2022-12-21 ONK Therapeutics Limited Cellules tueuses naturelles modifiées et leurs utilisations
JP6833851B2 (ja) * 2017-08-10 2021-02-24 グリフォルズ ダイアグノスティック ソリューションズ インコーポレイティド 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット
WO2019035938A1 (fr) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à bcma et leurs utilisations
CA3079242A1 (fr) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methodes de traitement du myelome multiple a haut risque
JP6648171B2 (ja) * 2018-02-02 2020-02-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
MA52640A (fr) * 2018-05-16 2021-03-24 Janssen Biotech Inc Procédés de traitement de cancers et d'amélioration de l'efficacité d'agents thérapeutiques de redirection de lymphocytes t
EP3820890A1 (fr) 2018-07-13 2021-05-19 Genmab A/S Thérapie à médiation par trogocytose utilisant des anticorps cd38
KR20210031932A (ko) 2018-07-13 2021-03-23 젠맵 에이/에스 Cd38 항체의 변이체 및 그의 용도
WO2020072840A1 (fr) * 2018-10-03 2020-04-09 Prescient Pharma Llc Compositions et méthodes pour isoler des cellules circulantes
TW202102541A (zh) 2019-03-15 2021-01-16 德商莫菲西斯公司 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物
CN113993543B (zh) 2019-06-10 2024-07-12 武田药品工业株式会社 使用抗cd38抗体的组合疗法
GB201916150D0 (en) 2019-11-06 2019-12-18 Univ Of Ireland Galway Treatment of multiple myeloma
CN112876563B (zh) 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
JP6853392B2 (ja) * 2020-01-15 2021-03-31 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
WO2021144457A1 (fr) 2020-01-16 2021-07-22 Genmab A/S Formulations d'anticorps anti-cd38 et leurs utilisations
MX2022010549A (es) 2020-02-26 2022-11-16 Biograph 55 Inc Moleculas de union compuestas que se dirigen a celulas b inmunodepresoras.
EP4121112A4 (fr) 2020-05-08 2023-11-15 The University Of Southern California Conjugués anticorps-médicament spécifiques au site par adp-ribosyl cyclases
US20240101695A1 (en) * 2020-09-01 2024-03-28 The Regents Of The University Of California Immunoglobulin e antibody compositions and methods of use
MX2023008187A (es) 2021-01-14 2023-07-18 Morphosys Ag Anticuerpos anti-cd38 y sus usos.
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
WO2024094660A1 (fr) 2022-10-31 2024-05-10 Genmab A/S Anticorps cd38 et leurs utilisations
US12173081B2 (en) 2023-03-21 2024-12-24 Biograph 55, Inc. CD19/CD38 multispecific antibodies

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1989008114A1 (fr) 1988-02-25 1989-09-08 The General Hospital Corporation Procede de clonage par immunoselection rapide
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (fr) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methode de production de chainons de paires de liaison specifique
EP0551301A1 (fr) 1990-07-13 1993-07-21 The General Hospital Corporation Antigene de surface de cellule cd53 et son utilisation
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1994025585A1 (fr) 1993-04-26 1994-11-10 Genpharm International, Inc. Animaux transgeniques capables de produire des anticorps heterologues
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
CA2105300C (fr) 1991-03-01 2008-12-23 Robert C. Ladner Procede pour le developpement de mini-proteines fixatrices
EP0580737B1 (fr) 1991-04-10 2004-06-16 The Scripps Research Institute Banques de recepteurs heterodimeres utilisant des phagemides
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
CA2113113A1 (fr) 1991-07-08 1993-01-21 Simon W. Kantor Copolymere sequence a cristaux liquides thermotropiques
WO1993006213A1 (fr) 1991-09-23 1993-04-01 Medical Research Council Production d'anticorps chimeriques - une approche combinatoire
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
WO1994017184A1 (fr) 1993-01-29 1994-08-04 Schering Corporation Modulation de la reponse physiologique de lymphocytes par les molecules cd38 ou leurs anti-corps
WO1994019935A1 (fr) 1993-03-09 1994-09-15 Genzyme Corporation Isolement de constituants d'interet du lait
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
JP4233608B2 (ja) 1996-10-15 2009-03-04 塩野義製薬株式会社 自己抗体測定方法
US6083477A (en) 1996-10-17 2000-07-04 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
WO2000006194A2 (fr) 1997-02-05 2000-02-10 Biotransplant, Inc. Depletion de cellules responsables du rejet d'une greffe induit par des anticorps
JP3835827B2 (ja) 1997-05-02 2006-10-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンティッド バイ ザ セクレタリーオブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 悪性細胞に対する、ｏｎｃタンパク質を含む、免疫毒素
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6719977B1 (en) 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
JP2002509716A (ja) 1998-03-31 2002-04-02 ユニバーシティ テクノロジー コーポレイション テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物
EP1085882A2 (fr) * 1998-06-05 2001-03-28 Mayo Foundation For Medical Education And Research Traitement du myelome multiple au moyen d'anticorps du cd38 obtenus par genie genetique
US6455043B1 (en) * 1998-08-11 2002-09-24 Idec Pharmaceuticals Corporation Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
US20050037969A1 (en) * 1999-05-14 2005-02-17 Arbor Vita Corporation Molecular interactions in hematopoietic cells
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
EP1174440A1 (fr) 2000-07-19 2002-01-23 U-BISys B.V. Un épitope exprimé sélectivement sur la molécule humaine CD38 et détecté par un fragment d'un anticorps humain de forme scFv dérivé d'une librairie "phage display"
US20070042436A1 (en) 2000-10-17 2007-02-22 Lund Frances E CD38 modulated chemotaxis
CA2424643A1 (fr) 2000-10-17 2002-04-25 Trudeau Institute, Inc. Chimiotaxie modulee du gene cd38
US6713055B2 (en) 2000-11-27 2004-03-30 Geron Corporation Glycosyltransferase vectors for treating cancer
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
HUP0600225A3 (en) 2001-06-13 2010-01-28 Genmab As Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US20040166490A1 (en) 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20040019915A1 (en) * 2002-04-01 2004-01-29 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
EP1393720A1 (fr) 2002-08-27 2004-03-03 Universiteit Utrecht Vesicules encapsulant des corticosteroides pour le traitement du cancer
MXPA05004022A (es) 2002-10-17 2005-10-05 Genmab As Anticuerpos monoclonales humanos contra cd20.
JP4966497B2 (ja) 2002-11-15 2012-07-04 ゲンマブ エー／エス Ｃｄ２５に対するヒトモノクローナル抗体
WO2004058797A2 (fr) 2002-12-16 2004-07-15 Medarex, Inc. Anticorps monoclonaux humains diriges contre l'interleukine 8 (il-8)
US7109304B2 (en) * 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US20070031406A1 (en) 2003-10-22 2007-02-08 Zand Martin S Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis
DK1684805T3 (da) * 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma
EA200600921A1 (ru) * 2003-11-06 2006-10-27 Селджин Корпорейшн Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
ES2541436T3 (es) 2004-02-06 2015-07-20 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
US8263746B2 (en) * 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
US20050266008A1 (en) * 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies
CN100416371C (zh) * 2004-04-21 2008-09-03 大日本印刷株式会社 彩色滤光片和具备该彩色滤光片的液晶显示装置
US20060019303A1 (en) * 2004-07-23 2006-01-26 Boehringer Ingelheim Pharmaceuticals, Inc. Method to identify and analyze genes having modified expression in stimulated T cells
CN119119271A (zh) 2005-03-23 2024-12-13 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
EP1888647A2 (fr) 2005-05-24 2008-02-20 MorphoSys AG Production et profilage d'anticorps therapeutiques entierement humains hucal gold®; propres a la molecule cd38 humaine
PT2081595T (pt) * 2006-09-26 2019-07-16 Genmab As Anti-cd38 mais corticosteroides mais um quimioterápico não corticosteroide para tratar tumores
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma

Also Published As

Publication number Publication date
CY2019037I1 (el) 2020-05-29
FR19C1056I1 (fr) 2019-11-15
LTPA2020520I1 (lt) 2020-07-27
CA2664740C (fr) 2021-11-16
LTPA2019515I1 (lt) 2019-10-25
FR21C1063I1 (fr) 2022-02-18
JP2016188228A (ja) 2016-11-04
CY2020016I2 (el) 2020-11-25
HUE044136T2 (hu) 2019-09-30
JP2021119198A (ja) 2021-08-12
HUS1900045I1 (hu) 2019-11-28
CY2020016I1 (el) 2020-11-25
AU2007302448C1 (en) 2019-02-14
AU2007302448B2 (en) 2013-12-19
HRP20191115T1 (hr) 2019-09-20
CY2021037I1 (el) 2022-03-24
CY2019036I2 (el) 2020-05-29
CY1121813T1 (el) 2020-05-29
RS59005B1 (sr) 2019-08-30
CY2021037I2 (el) 2022-03-24
HUS1900044I1 (hu) 2019-11-28
JP5476122B2 (ja) 2014-04-23
HUS2100056I1 (hu) 2022-01-28
EP2081595A2 (fr) 2009-07-29
US20100092489A1 (en) 2010-04-15
JP6607825B2 (ja) 2019-11-20
LTPA2019516I1 (lt) 2019-10-25
FR21C1062I1 (fr) 2022-02-18
EP3753576A1 (fr) 2020-12-23
US9040050B2 (en) 2015-05-26
IL197727A0 (en) 2011-08-01
SI2081595T1 (sl) 2019-10-30
EP2081595B1 (fr) 2019-04-10
US20150231235A1 (en) 2015-08-20
EA034877B1 (ru) 2020-04-01
LTPA2019514I1 (lt) 2019-10-25
TR201910145T4 (tr) 2019-08-21
LTPA2021014I1 (fr) 2022-01-10
CY2019037I2 (el) 2020-05-29
DK2081595T3 (da) 2019-07-15
LT2081595T (lt) 2019-07-10
FR19C1055I1 (fr) 2019-11-15
LUC00129I2 (fr) 2024-05-22
CY2021038I2 (el) 2023-11-15
IL248204A0 (en) 2016-11-30
US20200114000A1 (en) 2020-04-16
FR19C1057I1 (fr) 2019-11-15
JP2023120436A (ja) 2023-08-29
US20240165226A1 (en) 2024-05-23
JP2010504363A (ja) 2010-02-12
EA200970317A1 (ru) 2009-10-30
AU2013203186A1 (en) 2013-05-02
CY2019035I2 (el) 2020-05-29
ES2732278T3 (es) 2019-11-21
WO2008037257A2 (fr) 2008-04-03
LTPA2021015I1 (fr) 2022-01-25
EP3569245A1 (fr) 2019-11-20
PT2081595T (pt) 2019-07-16
HUS2100057I1 (hu) 2022-01-28
JP6907165B2 (ja) 2021-07-21
PL2081595T3 (pl) 2019-11-29
AU2013203186C1 (en) 2019-02-14
WO2008037257A3 (fr) 2008-06-05
IL197727A (en) 2017-01-31
ME03503B (fr) 2020-04-20
AU2007302448A1 (en) 2008-04-03
CY2021038I1 (el) 2022-03-24
LUC00130I2 (fr) 2024-05-22
NZ576122A (en) 2012-09-28
CA2664740A1 (fr) 2008-04-03
JP2014141492A (ja) 2014-08-07
HUS1900043I1 (hu) 2019-11-28
LUC00128I2 (fr) 2024-05-22
JP2019001804A (ja) 2019-01-10
AU2013203186B2 (en) 2016-06-16
CY2019036I1 (el) 2020-05-29
CY2019035I1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
FR21C1062I1 (fr) Traitement combiné de tumeurs exprimant la cd38
EP1982660A4 (fr) Endoscope de traitement
EP2046349A4 (fr) Traitement de la néovascularisation excessive
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
EP1996612A4 (fr) Compositions destinee au traitement des cancers
EP2338519A4 (fr) Agent de traitement d'une myélofibrose
BRPI0821779A2 (pt) tratamento terapêutico de câncer
EP2310006A4 (fr) Traitement du cancer
EP2005912A4 (fr) Instrument de traitement pour endoscope
EP1991230A4 (fr) Méthodes de traitement du cancer
BRPI0821660A2 (pt) Combinações de agentes terapêuticos para tratamento de câncer
BRPI0811265A2 (pt) Tratamento de sinucleinopatias
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
HUE043326T2 (hu) Akut limfoblasztos leukémia kezelése
EP2049139A4 (fr) Traitement de tumeurs exprimant ras
BRPI0912683A2 (pt) tratamento de tumores metastáticos
EP2032987A4 (fr) Traitement pharmacologique de la deficience cognitive
EP2307035A4 (fr) Traitement de l'épilepsie
EP2125002A4 (fr) Traitement du cancer de la peau
EP1943972A4 (fr) Instrument pour traitement endoscopique
EP2322109A4 (fr) Instrument de traitement pour endoscope
EP2367798A4 (fr) Traitement de la sclérose latérale amyotrophique
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
EP2387418A4 (fr) Traitement de la douleur